Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| International Stem Cell CORPISCO · Entity 8432 | Acting Chief Financial Officer | August 25, 2017 | August 30, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
International Stem Cell CORP
Report date August 25, 2017 · Filed August 30, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.25 · Expires 2027-08-25 | Direct | 150,000 |
Reported balance
After 2017-08-25 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-08-25 · Grant · Acquired 70,000 · Balance 150,000 F1: Upon becoming an officer of the company, the reporting person was awarded stock options. The option vest is 3/36th on initial vesting date (08/25/2017) and 1/36th for each additional full month of continuous service from the initial vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Upon becoming an officer of the company, the reporting person was awarded stock options. The option vest is 3/36th on initial vesting date (08/25/2017) and 1/36th for each additional full month of continuous service from the initial vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 25, 2017 Filed Aug 30, 2017 18:12 UTC | International Stem Cell CORP ISCO · Entity 8432 | GrantStock Option (Right to Buy) · Derivative | 70,000 | $1.25 Strike: $1.25 | $87,500.00 |
DisclosureSEC source: 0001683168-17-002253 · stephens_f4.xml · derivative · entry 1 Stephens Jennifer · CIK 0001715892 · Acting Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 70,000 shares Expires 2027-08-25 F1 · derivative.exercise_date: Upon becoming an officer of the company, the reporting person was awarded stock options. The option vest is 3/36th on initial vesting date (08/25/2017) and 1/36th for each additional full month of continuous service from the initial vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.